Krystal Biotech announced $116.4 million in global revenue for Q1 2026, a 32% increase year-over-year, driven by its gene therapy product VYJUVEK for dystrophic epidermolysis bullosa. The company completed enrollment in a key registrational study for KB803 and expects data readouts for KB803 and KB801 later in 2026. The FDA granted platform technology designations for KB407 and KB111, potentially accelerating development. Krystal ended the quarter with $1 billion in cash and investments, supporting ongoing trials and global expansion efforts.
Aptos Labs fixed a critical stale-cache bug in its Move virtual machine that could have allowed attackers to manipulate core blockchain data, risking up to $70 billion in assets. Security researchers demonstrated a proof-of-concept exploit with a 90%...
Aptos has fixed a critical vulnerability in its Move virtual machine that could have been exploited for only a few hundred dollars, posing a serious security risk. The flaw was discovered by ethical hackers and patched before any funds were lost or t...
On July 4, 2026, Ripple joined America250's Giving 4th campaign by pledging to match donations up to $10,000 in XRP to support the Call of Duty Endowment, which helps veterans find civilian jobs. Donors can contribute cash, stock, or cryptocurrency i...
SK Telecom announced plans to build an AI data center with a total capacity of 15GW, starting with 5GW to be activated in stages from 2029. This project aims to position Korea as a leading AI infrastructure hub in Asia, leveraging SK Group's full-sta...
Memecoin BONK surged over 10% in 24 hours with a 152% spike in trading volume, showing strong speculative interest as Bitcoin neared $64,000. Despite a longer-term bearish trend, BONK bounced 27.88% from its June low and is challenging a local resist...
